within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XK05_Veliparib;

model Veliparib
  extends Pharmacolibrary.Drugs.ATC.L.L01XK05;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01XK05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Veliparib (ATC code L01XK05) is a small molecule inhibitor of poly(ADP-ribose) polymerase (PARP) enzymes, used primarily in oncology as a targeted therapy for cancers such as ovarian and breast cancer, particularly in patients with BRCA mutations. Veliparib is not broadly approved as a monotherapy but has been investigated in combination with DNA-damaging chemotherapies in clinical trials.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with advanced solid tumors (mainly ovarian or BRCA-associated breast cancer) after single oral administration, median age 54, mixed sex.</p><h4>References</h4><ol><li><p>Nuthalapati, S, et al., &amp; Xiong, H (2018). Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination with Temozolomide in Subjects with Nonhematologic Malignancies. <i>Clinical pharmacokinetics</i> 57(1) 51–58. DOI:<a href=&quot;https://doi.org/10.1007/s40262-017-0547-z&quot;>10.1007/s40262-017-0547-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28497258/&quot;>https://pubmed.ncbi.nlm.nih.gov/28497258</a></p></li><li><p>Singh, R, et al., &amp; Beumer, JH (2019). Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias. <i>Cancer chemotherapy and pharmacology</i> 83(2) 319–328. DOI:<a href=&quot;https://doi.org/10.1007/s00280-018-3731-4&quot;>10.1007/s00280-018-3731-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30456480/&quot;>https://pubmed.ncbi.nlm.nih.gov/30456480</a></p></li><li><p>Li, J, et al., &amp; LoRusso, P (2014). Complex disease-, gene-, and drug-drug interactions: impacts of renal function, CYP2D6 phenotype, and OCT2 activity on veliparib pharmacokinetics. <i>Clinical cancer research : an official journal of the American Association for Cancer Research</i> 20(15) 3931–3944. DOI:<a href=&quot;https://doi.org/10.1158/1078-0432.CCR-14-0791&quot;>10.1158/1078-0432.CCR-14-0791</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24947923/&quot;>https://pubmed.ncbi.nlm.nih.gov/24947923</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Veliparib;
